A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/article/10.1007/s10549-018-4802-2/fulltext.html
Reference15 articles.
1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA: Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
2. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 14(8):2187–2194. https://doi.org/10.1245/s10434-007-9438-0
3. Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 132(4):620–626 (discussion 626–627)
4. Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20(9):2828–2834. https://doi.org/10.1245/s10434-013-2998-2
5. Thomas A, Khan SA, Chrischilles EA, Schroeder MC (2016) Initial surgery and survival in stage IV breast cancer in the united states, 1988–2011. JAMA Surg 151(5):424–431. https://doi.org/10.1001/jamasurg.2015.4539
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium;Breast Cancer Research and Treatment;2023-10-25
2. Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology;Frontiers in Oncology;2023-01-30
3. Metastatic breast cancer: Who benefits from surgery?;The American Journal of Surgery;2022-01
4. Factors Influencing Prognosis in Patients with <i>De Novo</i> Stage IV Breast Cancer: A Systematic Review and Meta-Analysis;SSRN Electronic Journal;2022
5. Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?;Critical Reviews in Oncology/Hematology;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3